Alivus Life Sciences Ltd.
ALIVUSNSEHealthcarePharmaceuticals & DrugsSmall Cap
₹1,070.3
▲ 0.97%
loading…
51
Composite
The company is in the business of making high-quality drugs by unlocking the possibilities of science.
Q-DITS fundamental score
51Composite
Growth
18
Profitability
76
Valuation
32
Quality
86
Solvency
70
Earnings
68
Key metrics
MCap
₹13.1K Cr
TTM PE
23.2x
Industry PE
38.2x
TTM EPS
₹45.99
Book Value
₹271.48
Face Value
₹2
Div Yield
0.47%
PEG
3.01x
PB
4.7x
ROE
18.9%
ROCE
25.5%
EBITDA mgn
29.9%
D/E
0
Int. Cover
272x
Curr. Ratio
4.97x
EPS
₹39.63
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | 6.9% | 5.7% | 6.2% | — |
| EBITDA | 16.8% | 7.5% | 6.2% | — |
| Net Profit | 20.2% | 7.7% | 10.7% | — |
Score snapshot
Piotroski
5/9
Altman Z
2.55
Quality
85.8
Growth
18.4
Valuation
32
Earn. Qual
67.9
PEAD
+2
SURGE
+1
Loading price data…
Loading delivery data…
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 8 years
Tap a row to expand the full chart
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | |
| ›EBITDACr | -0 | 248 | 484 | 592 | 631 | 671 | 686 | 717 | |
| ›EBITDA margin | -5.2% | 28% | 31.4% | 31.3% | 29.7% | 30.9% | 30% | 29.9% | |
| ›Net profitCr | -0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | |
| ›PAT margin | -175% | 22.1% | 20.3% | 18.6% | 19.7% | 21.5% | 20.6% | 20.3% | |
| ›EPS₹ | ₹-7.89 | ₹18.14 | ₹29.04 | ₹32.61 | ₹34.17 | ₹38.11 | ₹38.43 | ₹39.63 | |
| ›Revenue growth | 0% | 0% | 73.4% | 22.6% | 12.6% | 1.8% | 5.6% | 4.5% | |
| ›PAT growth | 0% | 0% | 60.1% | 12.3% | 19.1% | 11.5% | 0.8% | 3.1% | |
| ›ROE | 0% | 451.1% | 127.8% | 60.9% | 29.9% | 22.3% | 21.2% | 18.9% | |
| ›ROCE | 0% | 527.7% | 185.6% | 96.8% | 42.2% | 30% | 28.3% | 25.5% | |
| ›ROA | -510.6% | 26.5% | 19.6% | 17.8% | 16.6% | 15.4% | 14% | 13.3% | |
| ›P/E | 0x | 0x | 0x | 0x | 13.4x | 10.3x | 20.2x | 27.2x | |
| ›P/B | 0x | 0x | 0x | 0x | 2.7x | 2.3x | 4.1x | 4.7x | |
| ›D/E | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ›Current ratio | 0.1x | 0.7x | 0.9x | 1.1x | 2.8x | 2.3x | 4.4x | 5x | |
| ›Interest cover | — | 378.4x | 13.6x | 6.4x | 21.2x | 1,150.2x | 409.3x | 272x |
Quarterly results
Tap a row to expand the full chart
| Metric | Trend | 2023-12 | 2024-03 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | |
| ›Rev growth YoY | 5.9% | -13.6% | 1.8% | -14.9% | 12.1% | 21% | 2.2% | 16% | 4.8% | 6.1% | |
| ›EBITDACr | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | |
| ›EBITDA margin | 30.1% | 26.4% | 27.1% | 26.5% | 29.7% | 30.5% | 28.6% | 30.5% | 34.4% | 31.1% | |
| ›Net profitCr | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | |
| ›PAT growth YoY | 13.1% | -33.1% | -17.7% | -19.7% | 15.3% | 44.9% | 9% | 36.4% | 9.7% | 14.7% | |
| ›EPS₹ | ₹9.69 | ₹7.99 | ₹9.1 | ₹7.78 | ₹11.18 | ₹11.58 | ₹9.91 | ₹10.6 | ₹12.25 | ₹13.25 |
Balance sheet — last 9 years (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | -1 | 88 | 402 | 753 | 2,054 | 2,138 | 2,332 | 2,817 | 3,332 | |
| ›ReservesCr | -1 | 86 | 400 | 751 | 2,026 | 2,107 | 2,297 | 2,783 | 3,308 | |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ›InvestmentsCr | 0 | 8 | 9 | 11 | 20 | 10 | 701 | 839 | 0 | |
| ›Total assetsCr | -1 | 88 | 402 | 753 | 2,056 | 2,163 | 3,040 | 3,229 | 3,983 | |
| ›Current assetsCr | 0 | 931 | 1,160 | 1,623 | 2,127 | 2,369 | 1,916 | 2,335 | 2,649 | |
| ›Current liabilitiesCr | 1 | 1,380 | 1,307 | 1,445 | 747 | 1,015 | 439 | 470 | 508 | |
| ›Trade payablesCr | 0 | 183 | 201 | 221 | 308 | 427 | 369 | 390 | 372 | |
| ›Gross blockCr | 0 | 476 | 595 | 652 | 706 | 936 | 1,012 | 1,219 | 1,018 |
Cash flow statement (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | -0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 | |
| ›Investing CF (CFI)Cr | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 | |
| ›Financing CF (CFF)Cr | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 | |
| ›Net cash changeCr | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 | |
| ›Closing cashCr | 0 | 2 | 10 | 116 | 512 | 284 | 301 | 71 | 2 |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
51
Quality (25%)85.8
Growth (25%)18.4
Valuation (20%)32
Piotroski (15%)56
Earnings Quality (10%)67.9
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
5/9
✓ROA positiveROA 13.34%
✓CFO positiveCFO ₹565.41 Cr
✗ROA improving13.96% → 13.34%
✓CFO > PAT (low accruals)CFO 565.41 vs PAT 485.63
✗Leverage decreasedD/E 0.0 → 0.0
✓Liquidity improvedCR 4.37 → 4.97
✓No share dilutionEPS 38.43 → 39.63
✗Margin improvedEBITDA mgn 29.97% → 29.92%
✗Asset turnover upAsset TO 0.68 → 0.66
Altman Z-Scoregrey
2.55
X1
0.538
X2
0.83
X3
0.165
X4
0.837
X5
0.599
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
85.8/100
ROE
18.9%
ROCE
25.5%
Margin
20.3%
Debt
0
Int. cover
272x
Growth
18.4/100
Revenue 3Y
5.7%
Profit 3Y
7.7%
EPS
3.1%
Valuation
32/100
PE
27.2x
PB
4.7x
EV/EBITDA
18.4x
vs universe median: PE 25.6x · PB 2.81x · EV 13.41x
Earnings quality
67.9/100
CFO₹565 Cr
PAT₹486 Cr
Accrual ratio-0.02
CFO/PAT1.16x
PEAD · SURGE
+2 / +1
Revenue SUE0.19
EPS SUE2.22
Latest quarter2026-03
Rev growth YoY6.1%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,794 | 58,462 | 11,565 | 38.4x | 5.3x | 16.2 | 19.9 | 0.03 |
| Divi's Laboratories Ltd. | 1,78,956 | 10,560 | 2,568 | 69.7x | 10.7x | 15.4 | 20.5 | 0 |
| Torrent Pharmaceuticals Ltd. | 1,49,820 | 13,980 | 2,138 | 69.3x | 17.9x | 26.8 | 19.3 | 1.76 |
| Cipla Ltd. | 1,09,370 | 28,163 | 3,870 | 28.2x | 3.2x | 11.8 | 16 | 0.01 |
| Lupin Ltd. | 1,07,537 | 27,958 | 5,355 | 20.2x | 4.8x | 21.1 | 22 | 0.3 |
| Zydus Lifesciences Ltd. | 1,06,823 | 27,148 | 5,026 | 21.2x | 4x | 21.1 | 26.1 | 0.13 |
| Dr. Reddy's Laboratories Ltd. | 1,06,133 | 33,700 | 4,144 | 25.3x | 2.8x | 18.6 | 23.3 | 0.14 |